Now live: Pro — the full 13F research suite for serious investorsSee pricing →
NVP Associates, LLC

Q4 2024 · 13F-HR

NVP Associates, LLCholdings as filed

Filed 2025-02-10 · accession 0001104659-25-010945

$186.9M
Reported value
7
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
23834J201DAVEDAVE INC$50.6M27.1%582,675CommonSOLE
87427V103TALKTALKSPACE INC$45.4M24.3%14,702,972CommonSOLE
55287L101MBXMBX BIOSCIENCES INC$39.4M21.1%2,136,335CommonSOLE
9026851067WHUDEMY INC$25.6M13.7%3,114,732CommonSOLE
98937L105ZBIOZENAS BIOPHARMA INC$15.1M8.05%1,838,482CommonSOLE
683712103OPENOPENDOOR TECHNOLOGIES INC$6.7M3.59%4,189,562CommonSOLE
39957D201GROVGROVE COLLABORATIVE HOLD INC$4.1M2.19%2,943,522CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.